Drug Eruption and Interactions - PHARMACEUTICAL REVIEW
Share Embed Flag
Download ePaper

Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

Drug Eruption and Interactions - PHARMACEUTICAL REVIEW Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

pharmareview.files.wordpress.com
from pharmareview.files.wordpress.com More from this publisher
02.06.2013 Views

(2001): Vogel CL+, Oncology 61, 37 (2000): Treish I+, Am J Health Syst Pharm 57(22), 2063 (1999): Goldenberg MM, Clin Ther 21(2), 309 Cough (26%) (1999): Goldenberg MM, Clin Ther 21(2), 309 Death (2002): McKeage K+, Drugs 62(1), 209 Fever (2005): Baselga J+, J Clin Oncol 23(10), 2162 (2004): Sawaki M+, Tumori 90(1), 40 (11%) Infections (20%) (1999): Goldenberg MM, Clin Ther 21(2), 309 Injection-site reactions (sic) (

552 TRAZODONE Hair Hair – alopecia (2000): Mercke Y+, Ann Clin Psychiatry 12, 35 (1988): Warnock JK+, Am J Psychiatry 145, 425 Nails Nails – leukonychia (1985): Longstreth GF+, JAmAcadDermatol13, 149 Other Gynecomastia Hypersensitivity Myalgia/Myositis/Myopathy/Myotoxicity (1–10%) TREPROSTINIL Trade name: Remodulin (United) Indications: Pulmonary arterial hypertension Category: Platelet aggregation inhibitor; Prostaglandin Half-life: 2–4 hours Clinically important, potentially hazardous interactions with: anticoagulants, antihypertensives, diuretics, vasodilators Reactions Skin Diaphoresis Edema (9%) (2002): Horn EM+, Expert Opin Investig Drugs 11(11), 1615 Erythema Peripheral edema Pruritus (8%) Rash (sic) (14%) Other Application-site reactions (sic) (83%) Injection-site bleeding (33%) Injection-site erythema (2002): Horn EM+, Expert Opin Investig Drugs 11(11), 1615 Injection-site induration Injection-site pain (85%) (2002): Horn EM+, Expert Opin Investig Drugs 11(11), 1615 (2002): Simonneau G+, Am J Respir Crit Care Md 165(6), 800 (2002): Vachiery JL+, Chest 121(5), 1561 Injection-site reactions (sic) (83%) Pain (13%) (2002): Horn EM+, Expert Opin Investig Drugs 11(11), 1615 TRETINOIN Synonym: All-trans-retinoic acid Trade names: A-Acido; Aberal; Aberela; Acid A Vit; Acnavit; Acta; Airol; Aknemycin Plus (EM Industries); Alquingel; Alten; ATRA; Atragen; Avita; Avitcid; Avitoin; Cordes VAS; Derm A; Dermairol; Dermojuventus; Epi-Aberel; Eudyna; Relief; Renova (Ortho); Retin-A Micro (Ortho); Retinoic Acid; Retinova; Solage (Galderma); SteiVAA; Stieva-A; Vesanoid (Roche); Vitamin A Acid Indications: Acne vulgaris, skin aging, facial roughness, fine wrinkles, hyperpigmentation [T], acute promyelocytic leukemia (APL) [O] Category: Retinoid Half-life: 0.5–2 hours Clinically important, potentially hazardous interactions with: aldesleukin, bexarotene Note: [T] = Topical, [O] = Oral Reactions Skin Acne (1%) (1996): Shalita A+, JAmAcadDermatol34, 482 Acute febrile neutrophilic dermatosis (Sweet’s syndrome) (2007): Jagdeo J+, JAmAcadDermatol56(4), 690 (2007): Thompson DF+, Ann Pharmacother 41(5), 802 (2005): Shimizu D+, Intern Med 44(5), 480 (2004): Al-Saad K+, J Pediatr Hematol Oncol 26(3), 197 (2002): Astudillo L+, Ann Hematol 81(2), 111 (2001): Park CJ+, Korean J Intern Med 16(3), 218 (2000): Ueno R+, Rinsho Ketsueki 41(9), 718 (2000): van Der Vliet HJ+, Am J Hematol 63(2), 94 (1999): Levi I+, Leuk Lymphoma 34(3–4), 401 (1999): Takada S+, Int J Hematol 70(1), 26 (1998): Arun B+, Leuk Lymphoma 31(5–6), 613 (1997): Hatake K+, Int J Hematol 66(1), 13 (1996): Christ E+, Leukemia 10(4), 731 (1995): Shirono K+, Int J Hematol 62(3), 183 (1994): Cox NH+, Clin Exp Dermatol 19(1), 51 (1994): Piette WW+, JAmAcadDermatol30(2 Pt 2), 293 (1994): Tomas JF+, Leukemia 8(9), 1596 Bullous dermatitis (1998): Webster GF, JAmAcadDermatol39, S38–44 (1997): Cunliffe WJ+, JAmAcadDermatol36, S126–34 Burning (10–40%) [O][T] (2001): Egan N+, Cutis 68(4 Suppl), 20 (2001): Vandana B+, AAPS PharmSciTech 2(3), Technical Note 4 (1998): Ellis CN+, Br J Dermatol 139 Suppl 52, 41 (1998): Webster GF, JAmAcadDermatol39, S38 (1997): Drug Information Handbook Fifth Ed., American Pharmaceutical Association Hudson, OH (1997): Cunliffe WJ+, JAmAcadDermatol36, S126 (1997): Gilchrest B, JAmAcadDermatol36, S27–36 (1996): Shalita A+, JAmAcadDermatol34, 482 (1996): Shroot B, Presented at Dermatology Update ‘95 (Montreal) (Canada) (1995): Package Insert Hoffman-LaRoche, Inc. Nutley, NJ (1995): Hall R, Inpharma December, 13 (1992): Olsen EA+, JAmAcadDermatol26, 215 (1991): Weinstein GD+, Arch Dermatol 127, 659 (1989): Goldfarb MT+, JAmAcadDermatol21, 645 (1989): Leyden JJ+, JAmAcadDermatol21, 638 (1988): Cohen BA+, Pediatric Dermatology 1, New York: Churchill Livingstone, 663 Carcinoma [O] Cellulitis (1–10%) [O] (1997): Drug Information Handbook Fifth Ed., American Pharmaceutical Association Hudson, OH (1995): Package insert Hoffman-LaRoche, Inc. Nutley, NJ (1995): Gillis JC+, Drugs 50(5), 897 Crusting (1998): Webster GF, JAmAcadDermatol39, S38 (1997): Cunliffe WJ+, JAmAcadDermatol36, S126 Dermatitis (1997): Gilchrest B, JAmAcadDermatol36, S27 (1992): Olsen EA+, JAmAcadDermatol26, 215 (1991): Weinstein GD+, Arch Dermatol 127, 659 (1989): Goldfarb MT+, JAmAcadDermatol21, 645 (1989): Leyden JJ+, JAmAcadDermatol21, 638 Desquamation (14%) Diaphoresis (20%) Edema (29%) (1998): Webster GF, JAmAcadDermatol39, S38 (1997): Drug Information Handbook Fifth Ed. American Pharmaceutical Association, Hudson, OH (29%) ([O]) (1997): Cunliffe WJ+, JAmAcadDermatol36, S126

(2001): Vogel CL+, Oncology 61, 37<br />

(2000): Treish I+, Am J Health Syst Pharm 57(22), 2063<br />

(1999): Goldenberg MM, Clin Ther 21(2), 309<br />

Cough (26%)<br />

(1999): Goldenberg MM, Clin Ther 21(2), 309<br />

Death<br />

(2002): McKeage K+, <strong>Drug</strong>s 62(1), 209<br />

Fever<br />

(2005): Baselga J+, J Clin Oncol 23(10), 2162<br />

(2004): Sawaki M+, Tumori 90(1), 40 (11%)<br />

Infections (20%)<br />

(1999): Goldenberg MM, Clin Ther 21(2), 309<br />

Injection-site reactions (sic) (

logo

products

Resources

Company

Terms of service
Privacy policy
Cookie policy
Cookie settings
Imprint
Change language
Made with love in Switzerland
© 2024 Yumpu.com all rights reserved

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!